Furthermore, our results demonstrated that EPDR1/TRPC1 inhibited the proliferation, migration, invasion, and interstitial-related protein expression of epirubicin-treated resistant BC cells by suppressing PI3K/AKT signaling pathway and increased the sensitivity of epirubicin-resistant BC cells. Here, AKT1 is linked to breast cancer.